Iovance Biotherapeutics is a clinical-stage biopharmaceutical company developing a transformational approach to cure cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells in each patient. Tumor infiltrating lymphocyte therapy is an autologous, polyclonal cell therapy platform technology that was developed by the National Cancer Institute which conducted initial clinical trials of this therapy in diseases such as metastatic melanoma and cervical cancer. Co.'s primary product candidates include lifileucel for metastatic melanoma and metastatic cervical cancer, as well as LN-145 for metastatic non-small cell lung cancer. The IOVA stock yearly return is shown above.
The yearly return on the IOVA stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2023 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the IOVA annual return calculation with any dividends reinvested as applicable (on ex-dates).
|